Literature DB >> 31083383

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer.

Rasha M Sareyeldin1,2, Ishita Gupta3,4, Israa Al-Hashimi5,6, Hamda A Al-Thawadi7, Halema F Al Farsi8, Semir Vranic9, Ala-Eddin Al Moustafa10,11.   

Abstract

Breast cancer is the second most common cause of cancer-related deaths among women worldwide. It is a heterogeneous disease with four major molecular subtypes. One of the subtypes, human epidermal growth factor receptor 2 (HER2)-enriched (HER2-positive) is characterized by the absence of estrogen and progesterone receptors and overexpression of HER2 receptor, and accounts for 15-20% of all breast cancers. Despite the anti-HER2 and cytotoxic chemotherapy, HER2 subtype is an aggressive disease with significant mortality. Recent advances in molecular biology techniques, including gene expression profiling, proteomics, and microRNA analysis, have been extensively used to explore the underlying mechanisms behind human breast carcinogenesis and metastasis including HER2-positive breast cancer, paving the way for developing new targeted therapies. This review focuses on recent advances on gene expression and miRNA status in HER2-positive breast cancer.

Entities:  

Keywords:  HER2-positive breast cancer; biomarkers; breast cancer; gene expression profiling; miRNAs; microarray

Year:  2019        PMID: 31083383      PMCID: PMC6562440          DOI: 10.3390/cancers11050646

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  15 in total

Review 1.  Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis.

Authors:  Busra Buyuk; Sha Jin; Kaiming Ye
Journal:  Cell Mol Bioeng       Date:  2021-09-02       Impact factor: 3.337

2.  Subtype specific targeting of calcium signaling in breast cancer.

Authors:  Monish Ram Makena; Rajini Rao
Journal:  Cell Calcium       Date:  2019-11-12       Impact factor: 6.817

3.  Immunomagnetic bead-based bioassay for the voltammetric analysis of the breast cancer biomarker HER2-ECD and tumour cells using quantum dots as detection labels.

Authors:  Maria Freitas; Henri P A Nouws; Elisa Keating; Virginia Cruz Fernandes; Cristina Delerue-Matos
Journal:  Mikrochim Acta       Date:  2020-02-22       Impact factor: 5.833

4.  Characterization of T-DM1-resistant breast cancer cells.

Authors:  Juliette Sauveur; Louise Conilh; Sabine Beaumel; Kamel Chettab; Lars-Petter Jordheim; Eva-Laure Matera; Charles Dumontet
Journal:  Pharmacol Res Perspect       Date:  2020-08

5.  Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells.

Authors:  Ayesha Jabeen; Anju Sharma; Ishita Gupta; Hadeel Kheraldine; Semir Vranic; Ala-Eddin Al Moustafa; Halema F Al Farsi
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

Review 6.  Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets.

Authors:  Ishita Gupta; Balsam Rizeq; Semir Vranic; Ala-Eddin Al Moustafa; Halema Al Farsi
Journal:  Int J Mol Sci       Date:  2020-09-15       Impact factor: 5.923

7.  Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.

Authors:  Kitti Andreidesz; Balazs Koszegi; Dominika Kovacs; Viola Bagone Vantus; Ferenc Gallyas; Krisztina Kovacs
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

8.  Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.

Authors:  Wende Li; Sen Li; Ivy X Chen; Yujiao Liu; Rakesh R Ramjiawan; Chi-Ho Leung; Leo E Gerweck; Dai Fukumura; Jay S Loeffler; Rakesh K Jain; Dan G Duda; Peigen Huang
Journal:  Radiat Oncol       Date:  2021-03-04       Impact factor: 3.481

9.  The long non-coding RNA LOC285758 promotes invasion of acute myeloid leukemia cells by down-regulating miR-204-5p.

Authors:  Fangfang Xue; Haiyan Che
Journal:  FEBS Open Bio       Date:  2020-03-26       Impact factor: 2.693

10.  Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Authors:  Sasagu Kurozumi; Mansour Alsaleem; Cíntia J Monteiro; Kartikeya Bhardwaj; Stacey E P Joosten; Takaaki Fujii; Ken Shirabe; Andrew R Green; Ian O Ellis; Emad A Rakha; Nigel P Mongan; David M Heery; Wilbert Zwart; Steffi Oesterreich; Simon J Johnston
Journal:  Breast Cancer Res       Date:  2020-08-11       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.